Literature DB >> 16252078

Use of non-invasive phase contrast magnetic resonance imaging for estimation of atrial septal defect size and morphology: a comparison with transesophageal echo.

Chin Sze Piaw1, Ong Tiong Kiam, Annuar Rapaee, Liew Chee Khoon, Liew Houng Bang, Chan Wei Ling, Hasri Samion, Sim Kui Hian.   

Abstract

BACKGROUND: Transesophageal echocardiography (TEE) is a trusted method of sizing atrial septal defect (ASD) prior to percutaneous closure but is invasive, uncomfortable, and may carry a small risk of morbidity and mortality. Magnetic resonance imaging (MRI) may be useful non-invasive alternative in such patients who refuse or are unable to tolerate TEE and may provide additional information on the shape of the A0SD.
PURPOSE: To validate the accuracy of ASD sizing by MRI compared with TEE.
METHOD: Twelve patients (mean age 30 years; range 11-60 years) scheduled for ASD closure underwent TEE, cine balanced fast field echo MRI (bFFE-MRI) in four-chamber and sagittal views and phase-contrast MRI (PC-MRI) with reconstruction using the two orthogonal planes of T2-weighted images as planning. The average of the three longest measurements for all imaging modalities was calculated for each patient.
RESULTS: Mean maximum ASD length on TEE was 18.8 +/- 4.6 mm, mean length by bFFE-MRI was 20.0 +/- 5.0 mm, and mean length by PC-MRI was 18.3 +/- 3.6 mm. The TEE measurement was significantly correlated with the bFFE-MRI and PC-MRI measurements (Pearson r = 0.69, p = 0.02 and r = 0.59, p = 0.04, respectively). The mean difference between TEE and bFFE-MRI measurements was -1.2mm (95% CI: -3.7, 1.3) and between TEE and PC-MRI was 0.5 mm (95% CI: -1.9, 2.9). Bland-Altman analysis also determined general agreement between both MRI methods and TEE. The ASDs were egg-shaped in two cases, circular in 1 patient and oval in the remaining patients.
CONCLUSION: ASD sizing by MRI using bFFE and phase-contrast protocols correlated well with TEE estimations. PC-MRI provided additional information on ASD shapes and proximity to adjacent structures.

Entities:  

Mesh:

Year:  2006        PMID: 16252078     DOI: 10.1007/s00270-005-0003-6

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

Review 1.  Imaging congenital heart disease in adults.

Authors:  P J Kilner
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  [Clinical indications for the use of cardiac MRI. By the SIRM Study Group on Cardiac Imaging].

Authors:  E Di Cesare; F Cademartiri; I Carbone; A Carriero; M Centonze; F De Cobelli; R De Rosa; P Di Renzi; A Esposito; R Faletti; R Fattori; M Francone; A Giovagnoni; L La Grutta; G Ligabue; L Lovato; R Marano; M Midiri; A Romagnoli; V Russo; F Sardanelli; L Natale; J Bogaert; A De Roos
Journal:  Radiol Med       Date:  2012-11-26       Impact factor: 3.469

3.  Assessment of atrial septal defects in adults comparing cardiovascular magnetic resonance with transoesophageal echocardiography.

Authors:  Karen S L Teo; Patrick J Disney; Benjamin K Dundon; Matthew I Worthley; Michael A Brown; Prashanthan Sanders; Stephen G Worthley
Journal:  J Cardiovasc Magn Reson       Date:  2010-07-22       Impact factor: 5.364

Review 4.  The role of cardiovascular magnetic resonance in adults with congenital heart disease.

Authors:  Philip J Kilner
Journal:  Prog Cardiovasc Dis       Date:  2011 Nov-Dec       Impact factor: 8.194

5.  Phase contrast cardiac magnetic resonance imaging versus transoesophageal echocardiography for the evaluation of feasibility for transcatheter closure of atrial septal defects.

Authors:  Tariq Rashid Shah; Jahangir Rashid Beig; Naseer Ahmad Choh; Fayaz Ahmad Rather; Irfan Yaqoob; Vicar Mohammad Jan
Journal:  Egypt Heart J       Date:  2022-04-13

6.  Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology.

Authors:  Philip J Kilner; Tal Geva; Harald Kaemmerer; Pedro T Trindade; Juerg Schwitter; Gary D Webb
Journal:  Eur Heart J       Date:  2010-01-11       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.